Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Olokizumab in Asian RA Patients
NCT01533714Phase 2Terminated
- Sponsor
- UCB
- Start
- Jan 2012
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of olokizumab in rheumatoid arthritis (RA), sponsored by UCB. Started Jan 2012; status: terminated.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01533714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01533714.